Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine-Reference-Cited by-同舟云学术

Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine

Published:2002-05 Issue:5 Volume:46 Page:1586-1588
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Delaugerre Constance¹,Marcelin Anne-Geneviève¹,Thibault Vincent¹,Peytavin Gilles²,Bombled Tony¹,Bochet Marie-Valérie³⁴,Katlama Christine⁴,Benhamou Yves³,Calvez Vincent¹

Affiliation:

1. Departments of Virology

2. Department of Clinical Pharmacology, Bichat-Claude Bernard Hospital, Paris, France

3. Hepatology

4. Infectious Diseases, Pitié-Salpêtrière Hospital

Abstract

ABSTRACT Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.5.1586-1588.2002

Reference16 articles.

1. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl) phosphonylmethoxyethyl] adenine) in HIV-infected patients. J. Infect. Dis.176:406-413.

2. Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet358:718-723.

3. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay

4. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro

5. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis.176:1517-1523.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virtual Cocrystal Screening of Adefovir Dipivoxyl: Identification of New Solid Forms with Improved Dissolution and Permeation Profiles;Pharmaceutics;2022-10-27

2. Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease;Clinics in Liver Disease;2019-08

3. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013;HIV Medicine;2013-10-25

4. Antiviral therapies: Focus on hepatitis B reverse transcriptase;The International Journal of Biochemistry & Cell Biology;2012-07

5. Adefovir dipivoxil in chronic hepatitis B: history and current uses;Expert Opinion on Pharmacotherapy;2012-01-14